Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After an Abdominoplasty

NCT07102459 is registered in ClinicalTrials.gov with Latigo Biotherapeutics as lead sponsor.

NCT NCT07102459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07102459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After an Abdominoplasty
Lead sponsor
Latigo Biotherapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 24, 2025
Completion date
January 7, 2026
Enrollment
343 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute pain, postoperative pain control